
Arginine is an amino acid that is synthesized in the body. Oral arginine has been used for various conditions such as hypertension, angina, atherosclerosis, migraine headache, and erectile dysfunction. Its vasodilatory properties are thought to be responsible for the beneficial effects. Arginine has also been used to enhance wound healing, immune function, and athletic performance.
Some studies support use of arginine in coronary artery and peripheral artery diseases (PADs) (10) (11) (12) (13); however, long term supplementation of arginine can worsen PAD (14). Arginine along with antioxidant vitamins reduced the incidence of preeclampsia in high risk women (28). But arginine supplements did not improve blood pressure or kidney function in women with preeclampsia (15). Large doses of oral arginine improved subjective assessment of sexual function in men with organic erectile dysfunction (16). Arginine when combined with ibuprofen may increase pain relief in patients with migraine headaches (17). In addition, oral arginine has been studied for its effect on modifying or preventing the development of nitrate tolerance during continuous transdermal nitroglycerin therapy (18), and may enhance growth hormone release by inhibition of endogenous somatostatin (19). Arginine supplementation by enteral feeding was shown to decrease shock in severely burned patients (4).
Arginine supplementation has been studied in cancer patients. Postoperative enteral formulas enhanced with arginine may improve wound healing (1) and enhance immune status (27).
Nuts, seeds, soy foods, legumes, and chocolate.
Arginine is unique among amino acids for its vasodilatory properties (11). Arginine acts as a precursor for the synthesis of endogenous nitric oxide (NO) via the action of nitric oxide synthase (NOS). Nitric oxide's functions as a paracrine-signaling molecule mediating vasodilation and inhibition of platelet activation, monocyte and leucocyte adhesion, and smooth muscle cell proliferation. Nitric oxide also helps to control vascular oxidative stress and redox-regulated gene expression (22). Arginine is also needed for the synthesis of creatine which is important in muscle contraction (22). In colorectal adenoma cells, arginine reduces the expression of survivin, an inhibitor of apoptosis, and induces iNOS expression (23).
Absorption
Dietary arginine amounts to approximately 2-6g/day depending on protein intake levels (21). The kidney is the main organ for endogenous arginine synthesis from L-ornithine and L-citrulline precursors. The liver also synthesizes arginine, but it is reutilized in the urea cycle and therefore contributes little to plasma arginine fluctuations (22). After ingestion, a small amount of arginine is metabolized by the liver and the enterocytes (24). The enzyme arginase converts arginine to ornithine, with 50% of orally ingested arginine undergoing this route.
Distribution
Data on the pharmacokinetics of oral arginine in humans is limited. Animal studies found the highest tissue concentrations in the heart, skin, liver, small intestine and stomach (22).
Metabolism/Excretion
Half of orally ingested arginine are converted to ornithine by the enzyme arginase. Normally, most Arginine is reabsorbed in the kidneys.
High doses of intravenous arginine may results in the spillover into urine (22).
Okamoto Y, Okano K, Izuishi K, Usuki H, Wakabayashi H, Suzuki Y. Attenuation of the systemic inflammatory response and infectious complications after gastrectomy with preoperative oral arginine and omega-3 fatty acids supplemented immunonutrition. World J Surg. 2009 Sep;33(9):1815-21.
In this randomized study, 60 patients with gastric cancer received immune-enhanced formulas supplemented with arginine and omega-3 fatty acids (immune-enhancing diet, ID group) or standard formulas (conventional diet, CD group) for 7 days before they underwent gastrectomy. The postoperative outcome was determined based on infectious and noninfectious complications, and duration of systemic inflammatory response syndrome (SIRS). Researchers reported a significant reduction in the incidence of postoperative infectious complications in the ID group (6%) (p < 0.05) compared to those in the CD group (28%). The duration of SIRS in the ID group (0.77 +/- 0.9 days) was also significantly (p < 0.05) shorter than the CD group (1.34 +/- 1.45 days). Whereas the lymphocyte and CD4(+)T-cell counts significantly decreased (p < 0.05) in both groups, the number of CD4(+)T-cells on preoperative day 1 and postoperative day 7 was significantly (p < 0.05) higher in the ID group compared to the CD group.
Preoperative oral immune-enhancing formulas containing arginine and omega-3 fatty acids may benefit patients with gastric cancer by decreasing postoperative infectious complications.
Wilson AM, et al. L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation. Jul 10 2007;116(2):188-195.Because arginine supplementation provides short-term benefits to patients with peripheral artery disease (PAD), the objective of the Nitric Oxide in Peripheral Arterial Insufficiency (NO-PAIN) study, a prospective, randomized, double-blind, placebo-controlled trial, was to assess its long-term benefits. After 6 months of arginine (3 g/day) or placebo, 133 participants with PAD were examined for claudication distance and NO availability. Reduced improvements in NO, flow-mediated vasodilation, and walking distance were detected in participants receiving arginine as compared to the placebo group. The discordance between previously reported short-term studies and this long-term study may be due to unknown counterregulatory mechanisms such as arginase induction.
Lucotti P, et al. Beneficial effects of a long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients. Am J Physiol Endocrinol Metab. Nov 2006;291(5):E906-912.
The effect of arginine supplementation (8.3 g/day) was assessed in this study of 33 middle-aged, obese, type 2 diabetic participants undergoing an exercise training program and a hypocaloric diet. After 21 days, participants receiving arginine supplementation showed greater improvements in body composition as assessed by reduced fat mass and waste circumference as well as improved glucose tolerance as compared to the control group. Long-term studies are required to determine if arginine supplementation further reduces cardiovascular disease in these subjects.
Matsuda A, Takasaki H, Suzuki H, et al. Preoperative Oral Immune-Enhancing Nutritional Supplementation Corrects Th1/Th2 Imbalance in Patients Undergoing Elective Surgery for Colorectal Cancer. Dis Colon Rectum 2006 ;49(4):507-16.
Thirty-six patients with colorectal cancer scheduled for surgery were randomly divided into two groups; 19 patients received preoperative 750ml/day oral supplementation containing arginine, omega-3 fatty acids and ribonucleic acid for five days. The control group did not receive oral supplementation pre or post-operatively. Peripheral blood samples were drawn on the morning of surgery and 3, 7 and 14 days postoperatively. Flow cytometry determined the proportions of CD4+ T cells producing intracellular cytokines. Th1/Th2 balance shifted to Th2 dominance in the control group. Th2 dominance is associated with immune suppression in the cancer bearing state preoperatively, and surgical stress postoperatively. The supplemented group maintained the preoperative levels of Th1/Th2 until day 14. Preoperative immunonutrition may correct the altered Th1/Th2 balance in the preoperative cancer-bearing state and postoperatively.
Palloshi A, Fragasso G, Piatti P, et al. Effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests, and normal coronary arteries. Am J Cardiol. 2004;93(7):933-935.
Thirteen patients with grade 2 to 3 hypertension, microvascular angina and positive exercise tests received 2 grams of oral Arginine for 4 weeks. The patients were on full antihypertensive and antianginal therapy aimed at optimal control of blood pressure. Compared with baseline measurements, Arginine supplementation significantly decreased mean systolic blood pressure at rest (166 +/- 27 to 146 +/- 12 mm Hg; p<0.005). The frequency of angina attacks decreased from 12 +/- 3 to 4 +/- 1 per week, and nitroglycerin use decreased from 9 +/ 2 to 3 +/- 1 per week. The patients self-rated overall quality of life increased. (p values < 0.001) The authors suggest that Arginine may represent a useful therapeutic option for hypertension and microvascular angina, However, this study is based on a small sample size. Large well-designed clinical trials are needed to confirm this effect.
Bottom Line: Arginine has not been shown to treat cancer in humans.
Arginine is an amino acid that is produced by the body. It has been used for various conditions such as high blood pressure, heart conditions, migraine headaches and erectile dysfunction. Arginine has also been shown in clinical studies to enhance wound healing, immune function and athletic performance.
Immunomodulation
In this study 60 patients with gastric cancer received immune-enhanced formulas supplemented with arginine and omega-3 fatty acids (immune-enhancing diet, ID group) or standard formulas (conventional diet, CD group) for 7 days before they underwent gastric surgery. Pateints in the ID group had far fewer infectious complications compared to those in the CD group. Oral immune-enhancing formulas containing arginine and omega-3 fatty acids may benefit patients with gastric cancer by decreasing postoperative complications.
Thirty-six patients with colorectal cancer scheduled for surgery were divided into two groups. Each group received 750ml/day of arginine, omega-3 fatty acids and ribonucleic acid orally for 5 days. Blood test results showed that patients who received the oral supplements maintained the immune system cell count compared to those in the control group.
Peripheral artery disease
One hundred and thirty-three patients with peripheral artery disease received 3g of arginine/day or placebo for 6 months. Compared to previous study results (arginine supplementation for a shorter time), patients in the arginine group had reduced improvements in nitric oxide (important in maintaining proper blood flow to the organs) and walking distance compared to the placebo group. Long-term use of arginine may not be useful in patients with peripheral artery disease.
Diabetes
This study involved 33 obese, type-2 diabetic patients. Patients received 8.3 g of arginine/day or placebo and followed an exercise training program along with a low calorie diet. After 21 days, patients who received arginine showed greater improvements in body composition determined by reduced fat mass and waste circumference as well as improved glucose tolerance compared to the control group.
High Blood Pressure
In this study, 13 patients with hypertension and angina were given 2 grams of oral Arginine for 4 weeks. This was in addition to medication for hypertension and angina. Researchers observed a decrease in hypertension and angina attacks. Patients also reported improved quality of life.